Merck and Moderna’s late October 2026 release of Phase 3 INTerpath-001 data for their personalized mRNA vaccine intismeran, combined with pembrolizumab (Keytruda), drove recent trader sentiment by demonstrating a 42% reduction in melanoma recurrence or death and 38% lower risk of distant metastasis versus immunotherapy alone in over 1,100 high-risk patients. The companies immediately began engaging regulators for approval while analysts project a 2027 filing and launch, reflecting standard FDA review timelines for novel biologics rather than accelerated emergency authorization. Competitive dynamics center on mRNA’s neoantigen personalization versus earlier checkpoint inhibitors, with no other skin cancer vaccine candidates showing comparable late-stage results. Key upcoming catalysts include the full New England Journal of Medicine publication and any accelerated review decisions that could shift implied approval probabilities.